期刊文献+

张瑞霞益气补血法治疗原发性免疫性血小板减少症的医案一则 被引量:2

A case of Zhang Ruixia's Yiqi Buxue methods in treating primary immune thrombocytopenia
下载PDF
导出
摘要 原发性免疫性血小板减少症(Primary Immune Thrombocytopenia,ITP)部分患者对激素敏感性差,依赖丙种免疫球蛋白及输注血小板治疗,目前最有效的艾曲泊帕价格昂贵且不能保障临床安全。中医药治疗在血证方面有悠久的历史,其立足于整体观,通过多系统、多靶点、多途径发挥作用。张瑞霞先生认为气血为人体活动的本源,认为气血阴阳脏腑调和则人安;气血、阴阳、脏腑功能下降,疾病丛生,血证乃发。张瑞霞先生认为血证多因气血不足所致,其临证应用参芪四物汤加减治疗经验颇深。故举一住院病案以证明其疗效。 Some patients with primary immune thrombocytopenia have poor sensitivity to hormones and rely on gamma immunoglobulin and platelet transfusion therapy.At present,the most effective etrobopar is expensive and cannot guarantee clinical safety.TCM medicine treatment has a long history in the treatment of Xuezheng(血证).It is based on a holistic view and works through multiple systems,multiple targets,and multiple channels.Mr.Zhang Ruixia believes that Qi(气)and blood are the source of human activities,and that the harmony of Qi and blood,Yin(阴)and Yang(阳),and viscera will lead to peace;the functions of Qi and blood,Yin and Yang,and viscera are decreased,diseases are clustered,and Xuezheng is caused.Xuezheng are mostly caused by deficiency of Qi and blood,and clinical experience of Mr.Zhang Ruixia in applying the Shenqi Siwu decoction(参芪四物汤)on Xuezheng is quite deep.Therefore,a hospitalized medical record is given to prove its efficacy.
作者 白艳艳 高改娅 康艳 薛敬东 Bai Yanyan
出处 《中医临床研究》 2020年第26期37-39,共3页 Clinical Journal Of Chinese Medicine
基金 陕西省中医药管理局-长安医学张氏肝病流派传承工作室(2018)。
关键词 张瑞霞 参芪四物汤 原发性免疫性血小板减少症 气血不足证 医案举隅 Zhang Ruixia The Shenqi Siwu decoction Primary immune thrombocytopenia Qi and blood insufficiency syndrome Medical cases
  • 相关文献

二级参考文献27

  • 1ProvanD, StasiR, NewlandAC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia[J]. Blood,2010,115(2):168-186.
  • 2NeunertC, LimW, CrowtherM, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia[J]. Blood,2011,117(16):4190-4207.
  • 3British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy[J]. Br J Haematol,2003,120(4):574-596. doi:10.1046/j.1365-2141.2003.04131.x.
  • 4WeiY, JiXB, WangYW, et al. High-dose dexamethasone versus prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial[J]. Blood,2016,127(3):296-302. doi:10.1182/blood-2015-07-659656.
  • 5WangS, YangR, ZouP, et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia[J]. Int J Hematol,2012,96(2):222-228. doi:10.1007/s12185-012-1124-8.
  • 6BusselJB, ChengG, SalehMN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura[J]. N Engl J Med,2007,357(22):2237-2247. doi:10.1056/NEJMoa073275.
  • 7BusselJB, ProvanD, ShamsiT, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, doubleblind, placebo-controlled trial[J]. Lancet,2009,373(9664):641-648. doi:10.1016/S0140-6736(09)60402-5.
  • 8ChengG, SalehMN, MarcherC, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study[J]. Lancet,2011,377(9763):393-402. doi:10.1016/S0140-6736(10)60959-2.
  • 9SalehMN, BusselJB, ChengG, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study[J]. Blood,2013,121(3):537-545. doi:10.1182/blood-2012-04-425512.
  • 10KuterDJ, BusselJB, LyonsRM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial[J]. Lancet,2008,371(9610):395-403. doi:10.1016/S0140-6736(08)60203-2.

共引文献410

同被引文献53

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部